Sign In
Buy RHHVF
$433.64
-6.36 (-1.45%)
At Close: Jul 31, 2026
Roche Holding AG (RHHBY) Q2 2026 Earnings Call Transcript
02:20pm, Friday, 24'th Jul 2026
Roche Holding AG (RHHBY) Q2 2026 Earnings Call Transcript
Roche H1 Sales Decline on Currency Headwinds, Key Drugs Keep Momentum
03:21pm, Thursday, 23'rd Jul 2026
RHHBY posts 6% constant-currency sales growth in the first half of 2026 as strong demand for key drugs offsets legacy declines, while FDA pipeline progress supports momentum.
Roche Backs Full-Year View as First-Half Sales Rise
01:40am, Thursday, 23'rd Jul 2026
The drugmaker's sales grew 6% on a constant exchange rate basis and exceeded analysts' expectations, according to a company compiled consensus.
Roche confirms full year targets as first-half sales fall
01:17am, Thursday, 23'rd Jul 2026
Swiss drugmaker Roche confirmed its full-year targets on Thursday as first-half sales fell in Swiss franc terms, dragged down by a strong domestic currency.
RHHBY's Gazyva Gets FDA Priority Review for Label Expansion
01:10pm, Wednesday, 15'th Jul 2026
Roche wins FDA Priority Review for Gazyva in primary membranous nephropathy, with a decision due by November 2026 after positive phase III data.
The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
12:36pm, Wednesday, 08'th Jul 2026
Markets are being tested again. The AI trade has spent the past several weeks under real pressure, with memory, semiconductor, and neocloud names selling off hard after an extraordinary first half.
Roche Reports Positive Results From Head-to-Head Study on NSCLC Drug
02:46pm, Friday, 03'rd Jul 2026
RHHBY announces positive phase III Krascendo 1 results for divarasib in KRAS G12C NSCLC, showing PFS and OS gains versus approved inhibitors.
Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial
01:50am, Thursday, 02'nd Jul 2026
Experimental drug, divarasib, showed meaningful improvements in both patients' overall survival and the time they survived without the disease worsening.
Roche Gets FDA Priority Review for Enspryng in Thyroid Eye Disease
03:50pm, Tuesday, 30'th Jun 2026
Roche won FDA priority review for Enspryng in thyroid eye disease, with a decision date in October and phase III data backing the filing.
Roche launches Axelios gene sequencer in a bid to loosen Illumina's grip
04:07am, Monday, 29'th Jun 2026
Swiss pharma and diagnostics giant Roche on Monday launched its long-awaited Axelios gene sequencer, in a bid to challenge U.S. firm Illumina's leadership in next-generation sequencing.
EXEL Down on Colorectal Cancer Study Data on Zanzalintinib
03:26pm, Tuesday, 23'rd Jun 2026
Exelixis falls after STELLAR-303 misses statistical significance in overall survival for a key colorectal cancer subgroup, raising approval uncertainty.
U.S.-Iran deal will stick despite being a ‘bad, bad deal', says David Roche
12:15am, Friday, 19'th Jun 2026
Quantum Strategy's David Roche expects the US-Iran deal to hold, arguing both Washington and Tehran have strong incentives to keep Iranian oil flowing and avoid political disruption ahead of US midter
FDA Accepts Roche's Filing for Lunsumio VELO-Polivy in LBCL
01:50pm, Thursday, 18'th Jun 2026
FDA accepts RHHBY filing for Lunsumio VELO plus Polivy in relapsed or refractory LBCL as a potential chemotherapy-free treatment option.
FDA approves first generic version of Roche's flu drug
06:35pm, Wednesday, 17'th Jun 2026
The U.S. Food and Drug Administration approved the first generic version of Roche's Xofluza, a single-dose flu medicine for certain patients aged five years and older, the regulator said on Wedn
JAZZ's Zepzelca Fails to Meet Primary Goal in Lung Cancer Study
01:21pm, Monday, 15'th Jun 2026
Jazz Pharmaceuticals' Zepzelca fails a phase III lung cancer study, but strong first-line uptake and 2026 guidance remain unchanged.
